71OPhase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours. (25th November 2018) - Tan, D; Ng, M; Subbiah, V; Messersmith, W; Teneggi, V; Diermayr, V; Ethirajulu, K; Yeo, P; Gan, B H; Lee, L H; Blanchard, S; Nellore, R; et al.